Genentech Partners with 23andMe to Inform Its Parkinson’s Drug Development Efforts with WGS

January 7, 2015

(Genome Web) – Genentech will sequence the whole genomes of 3,000 people from 23andMe’s Parkinson’s disease community in an effort to identify drug targets, the companies announced today. Under the terms of the deal, 23andMe will be able to conduct additional research on the generated data once the project is completed. Additionally, 23andMe can share the data, scrubbed of patients’ identifying information, with other researchers. Only data from 23andMe customers who have consented to participate in the research will be shared, 23andMe said in a statement.